BioMap Completes its Series A Funding Round Valued at Over $100M

BioMap creates maps on illness targets and drug design using advanced computing and biotechnology to create Global First-in-Class unique pharmaceuticals.

FREMONT, CA: BioMap, a biological computing platform company, has recently completed the Series A funding round valued at over a hundred million U.S. dollars, which Legend Capital participated in. The funding will be used for research and development as well as talent recruitment.

BioMap is positioned as a cutting-edge medical research and development platform powered by a biological computer engine. Robin Li is the Chairman of the company, which he co-founded in November 2020. BioMap creates maps on illness targets and drug design using advanced computing and biotechnology to create Global First-in-Class unique pharmaceuticals. The business will also focus on the immunological mechanisms of cancers, autoimmune illnesses, and fibrotic diseases in the future.

Richard Li, the President of Legend Capital, said: “It is our second cooperation with Baidu this year after the investment in Baidu’s AI chip unit Kunlun in March. We hope to continue to maintain close cooperation with Baidu in the field of scientific and technological innovation in the future. We take a positive long-term view of the integration of IT and life science and technology. 

BioMap empowers life science with AI, and accelerates the R&D of new drugs and diagnostic products through the integration and innovation of AI technology and cutting-edge biotechnology. In the future, Legend Capital hopes to realize the full potential of the advantages of our enterprise ecosystem in the field of healthcare, and promote BioMap’s cooperation with leading companies in related fields, so as to provide intelligent computing platform support for the healthcare industry, give impetus to industrial upgrading and benefit more patients.”

Legend Capital has been devoting efforts to studying the deep integration of the healthcare and technology industries. It has delved deeper into the realm of medical AI in recent years. Legend Capital has also invested in AI microbial pharmaceutical organization Xbiome, AI innovative drug development platform StoneWise, AI medical image assisted diagnosis corporation Deepwise, Lunit, AI medical pathology diagnosis firm Deep Informatics, gene big data business Genowis, AI medical chronic disease management system company Ayshealth Technology, and others, in addition to BioMap.